A1,
A2,
B,
C1,
C2,
D,
E,
F,
G-H,
I-K,
L,
M,
N,
O,
P1,
P2,
Q-R,
S,
T,
U-V,
W-Z
Ultravate Pharmacology, Pharmacokinetics, Studies, Metabolism - Halobetasol Propionate
Ultravate Pharmacology, Pharmacokinetics, Studies, Metabolism - Halobetasol Propionate
CLINICAL PHARMACOLOGY
Like other topical corticosteroids, halobetasol propionate has anti-inflammatory,
antipruritic and vasoconstrictive actions. The mechanism of the anti-inflammatory
activity of the topical corticosteroids, in general, is unclear. However,
corticosteroids are thought to act by the induction of phospholipase A2
inhibitory proteins, collectively called lipocortins. It is postulated
that these proteins control the biosynthesis of potent mediators of inflammation
such as prostaglandins and leukotrienes by inhibiting the release of their
common precursor arachidonic acid. Arachidonic acid is released from membrane
phospholipids by phospholipase A2.
Pharmacokinetics
The extent of percutaneous absorption of topical corticosteroids is determined
by many factors including the vehicle and the integrity of the epidermal
barrier. Occlusive dressings with hydrocortisone for up to 24 hours have
not been demonstrated to increase penetration; however, occlusion of hydrocortisone
for 96 hours markedly enhances penetration. Topical corticosteroids can
be absorbed from normal intact skin. Inflammation and/or other disease
processes in the skin may increase percutaneous absorption.
Human and animal studies indicate that less than 6% of the applied dose
of halobetasol propionate enters the circulation within 96 hours following
topical administration of the cream.
Studies performed with ULTRAVATE (halobetasol propionate cream) Cream
indicate that it is in the super-high range of potency as compared with
other topical corticosteroids.
top
